Ritlecitinib治疗斑秃的长期安全性与疗效:ALLEGRO-LT 3期开放标签研究
ALLEGRO-LT是一项正在进行的3期开放标签研究,评估Ritlecitinib在成人及青少年斑秃患者中的长期安全性与疗效。新入组患者每日接受200mg负荷剂量4周后50mg治疗,至24个月时73.5%和66.4%患者达到SALT≤20和≤10,安全性可接受。
要点
- Ritlecitinib长期治疗斑秃至24个月显示持续疗效。
- 24个月时73.5%患者SALT≤20,66.4%患者SALT≤10。
- 安全性可接受,常见不良事件为轻中度。
核心结论
- 在斑秃且头皮脱发≥25%的患者中,Ritlecitinib长期治疗显示临床疗效且安全性可接受。
研究设计与样本
- ALLEGRO-LT为正在进行的长期、开放标签、多中心3期研究,报告新入组队列结果。
- 449例年龄≥12岁、斑秃且头皮脱发≥25%的新入组患者,每日接受200mg负荷剂量4周后50mg治疗。
- 分析基于截至2022年12月的数据,平均(SD)Ritlecitinib暴露时间为728.7(273.81)天。
主要发现
- 第24个月(as observed)时,73.5%和66.4%患者分别达到SALT评分≤20和≤10。
- 82.4%患者PGI-C应答为「中度改善」或「大幅改善」。
- 60.8%和65.7%患者分别达到眉毛评估(EBA)和睫毛评估(ELA)应答。
- 86.1%患者报告治疗中出现的不良事件,多为轻中度,最常见为SARS-CoV-2检测阳性(24.2%)、头痛(20.8%)和发热(13.0%)。
- 严重不良事件、严重不良事件和治疗中断率分别为4.9%、6.0%和6.5%;带状疱疹感染6例,严重感染4例,恶性肿瘤(除外非黑色素瘤皮肤癌)3例,主要不良心血管事件3例。
临床怎么用
- 对于斑秃且头皮脱发≥25%的成人及青少年患者,Ritlecitinib长期治疗可考虑用于改善毛发再生。
局限性
- 本研究为开放标签设计,缺乏对照组。
- 疗效结果为as observed分析,可能存在偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: ALLEGRO-LT is an ongoing, long-term, open-label, multicentre, phase 3 study of ritlecitinib in adults and adolescents with alopecia areata (AA). OBJECTIVES: To evaluate ritlecitinib safety and efficacy through Month 24 in patients with AA and ≥25% scalp hair loss. METHODS: ALLEGRO-LT enrolled rollover patients who previously received study intervention in either ALLEGRO phase 2a or 2b/3 studies and de novo patients who had not received treatment in either study. The de novo cohort results are reported here. Patients aged ≥12 years with AA and ≥25% scalp hair loss received a daily, 4-week 200-mg ritlecitinib loading dose, followed by daily 50-mg ritlecitinib. Analyses are based on data up to the cut-off (December 2022). Efficacy outcomes included proportions of patients achieving Severity of Alopecia Tool (SALT) scores ≤20 and ≤10, Patient Global Impression of Change (PGI-C) score of 'moderately improved' or 'greatly improved' and eyebrow assessment (EBA) and eyelash assessment (ELA) response (≥2-grade improvement from baseline or normal score in patients with abnormal baseline EBA/ELA). RESULTS: Mean (SD) ritlecitinib exposure among the 449 de novo patients enrolled was 728.7 (273.81) days. At Month 24 (as observed), 73.5% and 66.4% of patients achieved SALT score ≤20 and ≤10; 82.4% had PGI-C response; 60.8% and 65.7% had EBA and ELA response. 86.1% of patients reported treatment-emergent adverse events (AEs); most were mild or moderate in severity, with the most frequent being positive SARS-CoV-2 test (24.2%), headache (20.8%) and pyrexia (13.0%). Rates of serious AEs, severe AEs and treatment discontinuations were 4.9%, 6.0% and 6.5%, respectively. Herpes zoster infection occurred in six patients, serious infections in four, malignancies (excluding nonmelanoma skin cancer) in three and major adverse cardiovascular events in three. CONCLUSIONS: In patients with AA and ≥25% scalp hair loss, ritlecitinib demonstrated clinical efficacy and had an acceptable safety profile with long-term treatment. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT04006457.
引用
- Tziotzios C, Sinclair R, Lesiak A, et al. Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO-LT phase 3, open-label study. J Eur Acad Dermatol Venereol. 2025. PMID: 39846397. doi:10.1111/jdv.20526
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。